|
gptkbp:instanceOf
|
gptkb:drug
gptkb:PARP_inhibitor
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2014
|
|
gptkbp:ATCCode
|
L01XX46
|
|
gptkbp:bioavailability
|
gptkb:unknown
|
|
gptkbp:brand
|
gptkb:Lynparza
|
|
gptkbp:CASNumber
|
763113-22-0
|
|
gptkbp:category
|
gptkb:small_molecule
gptkb:targeted_therapy
orphan drug
|
|
gptkbp:chemicalFormula
|
C24H23FN4O3
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:discoveredBy
|
KuDOS Pharmaceuticals
|
|
gptkbp:discoveredIn
|
2005
|
|
gptkbp:drugClass
|
gptkb:antineoplastic_agent
|
|
gptkbp:eliminationHalfLife
|
11-12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasPatent
|
US7514414B2
|
|
gptkbp:indication
|
BRCA-mutated cancers
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits PARP enzymes
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:patent
|
gptkb:AstraZeneca
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
82%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521686
DB09074
23725625
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
diarrhea
fatigue
decreased appetite
|
|
gptkbp:target
|
gptkb:PARP1
gptkb:PARP2
|
|
gptkbp:UNII
|
7J2QW8QH6X
|
|
gptkbp:usedFor
|
gptkb:cancer
pancreatic cancer
prostate cancer
|
|
gptkbp:bfsParent
|
gptkb:PARP1
gptkb:PARP2
gptkb:Poly(ADP-ribose)_polymerase_1
gptkb:PARP
gptkb:L01XX43
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Olaparib
|